Testing the Effectiveness of AI Chatbots to Improve Public Knowledge and Attitudes Towards Depression
Launched by PEKING UNIVERSITY · Mar 3, 2025
Trial Information
Current as of October 01, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether AI chatbots can help people better understand depression and change how they feel about it. The goal is to see if using these chatbots can reduce negative attitudes towards depression and encourage more individuals to seek help when they need it. Participants will be divided into three groups: one will learn directly from an AI teacher about depression, another will learn from the AI teacher and then interact with an AI that simulates a person experiencing depression, and the third group will receive traditional education materials. The study will measure how much participants learn about depression, their willingness to seek help, and their confidence in supporting others.
To participate, you need to be between 18 and 65 years old, a native Chinese speaker, and not currently experiencing any mental health issues. You’ll need to be comfortable using the internet or a mobile device to interact with the AI. If you join, you can expect to engage in various activities designed to enhance your knowledge of depression in a friendly and supportive environment. This trial aims to find out if AI can make a positive difference in how people understand and talk about mental health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Adults aged 18 to 65.
- • 2. General population, non-clinical individuals.
- • 3. No history of diagnosed mental disorders or current mental health diagnosis.
- • 4. Ability to complete AI interactions and related tasks via the internet or mobile devices.
- • 5. Native Chinese speakers.
- • 6. Willingness to participate in the study and sign an informed consent form.
- Exclusion Criteria:
- • 1. History of mental disorders or self-reported current mental health issues.
- • 2. Currently undergoing psychological counseling.
- • 3. Inability to use mobile or internet devices properly.
About Peking University
Peking University is a prestigious institution located in Beijing, China, recognized for its commitment to advancing medical research and education. As a clinical trial sponsor, Peking University leverages its extensive academic resources and collaborative networks to drive innovative healthcare solutions. The university's focus on rigorous scientific methodologies and adherence to ethical standards ensures the integrity and reliability of its clinical research initiatives. By fostering interdisciplinary partnerships, Peking University aims to translate groundbreaking discoveries into tangible health benefits, contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported